* ACTINIUM PHARMACEUTICALS - WILL AMEND PROTOCOL OF SIERRA TRIAL TO EXPAND SALVAGE CHEMOTHERAPY REGIMENS AVAILABLE IN CONTROL ARM OF STUDY

* ACTINIUM PHARMACEUTICALS - SUPPLIED DOSIMETRIC & THERAPEUTIC DOSES TO PATIENTS IN STUDY ARM & THOSE THAT CROSSED OVER TO IOMAB-B ARM FROM CONTROL ARM

* ACTINIUM PHARMA -PATIENTS THAT CROSS OVER FROM CONTROL ARM COUNTED AS FAILURES FOR PRIMARY ENDPOINT OF DURABLE COMPLETE REMISSION OF AT LEAST 6 MONTHS Source text for Eikon: Further company coverage: